<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: October 26, 1999
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing that the Company had acquired technology to advance its lymphography
programs. The Press Release, dated October 26, 1999, is attached as Exhibit 99
hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated October 26, 1999, announcing that
the Company had acquired technology to advance its lymphography
programs.
1
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
----------------------
John Smolik, President
Date: October 26, 1999
2
<PAGE>
EXHIBIT INDEX
Exhibit Description
No.
99 Press release of the Company, dated October 26, 1999, announcing
that the Company had acquired technology to advance its
lymphography programs.
3
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
PHOTOGEN TECHNOLOGIES ANNOUNCES ACQUISITION OF TECHNOLOGY TO ADVANCE ITS
LYMPHOGRAPHY PROGRAMS
KEY METHODS AND MATERIALS TO COME FROM ALLIANCE PHARMACEUTICAL
CORP. AND MASSACHUSETTS GENERAL HOSPITAL
KNOXVILLE, TENN., OCT. 26, 1999 -- Photogen Technologies Inc. (OTC BB: PHGN)
today announced that it has acquired technology from Alliance Pharmaceutical
Corp. and Massachusetts General Hospital that will benefit Photogen's programs
in non-invasive lymphography and cancer treatments.
Lymphography is a procedure following the diagnosis of cancer that is used to
determine if cancer has spread to the lymph nodes.
From Alliance Pharmaceutical Corp., the Company acquired technology that
describes methods for using certain particulate contrast materials that follow
the course of tumor cells to the appropriate lymph node.
From Massachusetts General Hospital, the Company has licensed a special group of
nanoparticulate contrast materials, including one ready for a Phase II/III
clinical trial. The materials, which will be used in lymphography and other
applications, disseminate throughout the lymphatic system to quickly locate the
sentinel lymph nodes.
"This technology gives Photogen a very strong proprietary position in using
radiation and radiation-activated sensitizers to non-invasively diagnose and
treat cancer," said John Smolik, president and CEO.
Additional proprietary methods and materials, co-invented and recently improved
by Dr. Gerald Wolf, Photogen's medical director and professor emeritus at
Harvard University, complement Photogen's use of the radiosensitzer PH-10, by
expanding Photogen's proprietary position to include methods of administration
and treatment, and additional material agents.
"Photogen's origins are in combining light-based technologies with customized
photochemicals to diagnose and treat disease," said Dr. Wolf. "The acquisition
of the lymphography methods
<PAGE>
and materials will enable us to customize diagnostic and therapeutic treatments
by carefully selecting and merging pre-existing technology."
About Photogen
Photogen Technologies, Inc. is a development-stage company focused on creating
photodynamic-related healthcare products based on its proprietary multi-photon
excitation and other related technologies. The company has discovered new
methods for using light energy from lasers and X-rays to activate photoactive
agents within deep tissue sufficient to produce a range of beneficial
therapeutic and diagnostic outcomes. These technologies involve methods,
materials and devices that may be used to produce light and photoactive agents
that will destroy diseased cells, remove tissue or identify and diagnose
disease. Photogen's proprietary technology is covered under existing U.S.
patents and additional pending applications in the U.S. and worldwide. The
company has no products or operating revenues at this time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor provision
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's actual
results in the future to differ materially from expected results. These risks
and uncertainties include: the ability of the company to develop a product and
obtain regulatory approval for its use; the ability of the company to
successfully market and sell any products and equipment; the company's ability
to manufacture products in sufficient quantities; the company's ability to
maintain intellectual property protection for its proprietary products, to
defend its existing intellectual property rights from challenges by third
parties, and to avoid infringing intellectual property rights of third parties;
unforeseen operating risks; the company's ability to secure collaborative
agreements with third parties for various research, development, manufacturing,
marketing and other functions; competition; risks associated with the dependence
on manufacturers of the company's proposed products; the availability of capital
to finance planned activities; and the extent to which the clinicians performing
the procedures are able to obtain third-party reimbursement. These risks are
qualified in their entirety by cautionary language and risk factors set forth in
the company's filings with the Securities and Exchange Commission.
Media Contact: Hilary Kaye or Joan Murray at Hilary Kaye Associates
(714) 426-0444 (PST) or [email protected]
